Related Experiment Video

Updated: Aug 17, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Genetic determinants of methotrexate responsiveness and resistance in colon cancer cells

Cristina Morales1, Maria Ribas, Gemma Aiza

  • 1IDIBELL-Institut de Recerca Oncològica, Granvia km 2,7, L'Hospitalet, 08907 Barcelona, Spain.

Oncogene
|July 12, 2005
PubMed

Insights

Colon cancer cells’ genetic makeup influences their ability to resist chemotherapy. DHFR gene amplification is key for methotrexate resistance in some pathways, while microsatellite instability is linked in others.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Colorectal cancer exhibits diverse genetic pathways influencing disease progression.
  • Methotrexate (MTX) targets dihydrofolate reductase (DHFR), crucial for DNA synthesis.
  • Understanding chemoresistance mechanisms is vital for effective cancer treatment.

Purpose of the Study:

  • To investigate the relationship between distinct genetic profiles and methotrexate resistance in colon cancer cell lines.
  • To identify the genetic features associated with the development of MTX resistance.
  • To explore the role of DHFR gene amplification and microsatellite instability in chemoresistance.

Main Methods:

  • Utilized various colon cancer cell lines representing alternative genetic pathways.
  • Assessed genetic features including chromosomal aneuploidy and gene amplification.
  • Evaluated the development of MTX resistance and analyzed DHFR gene status and microsatellite instability.

Main Results:

  • Aneuploid cell lines with pre-existing amplifications showed varied responses to MTX; HT-29 developed resistance via DHFR gene amplification.
  • SW480 and SK-CO-1 cells failed to develop resistance, potentially due to chromosomal abnormalities.
  • Near-diploid and other aneuploid cell lines developed MTX resistance without DHFR amplification, correlating with microsatellite instability.

Conclusions:

  • Chemoresistance capacity is significantly influenced by the specific genetic pathway and karyotypic characteristics of colon cancer cells.
  • The mechanism of MTX resistance varies, involving DHFR amplification in some cases and microsatellite instability in others.
  • These findings highlight the importance of genetic profiling in predicting and understanding colon cancer chemoresistance.

More Related Videos

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...